INSMED INC Form SC 13G/A March 11, 2013

SCHEDULE 13G Amendment No. 4 Insmed Incorporated Common Stock Cusip #457669307 Cusip #457669307 Item 1: Reporting Person - FMR LLC Item 4: Delaware Item 5: 1,893,146 Item 6: 0 Item 7: 4,700,346 Item 8: 0 Item 9: 4,700,346 Item 11: 14.992% Item 12: HC Cusip #457669307 Item 1: Reporting Person - Edward C. Johnson 3d Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 4,700,346 Item 8: 0 Item 9: 4,700,346 Item 11: 14.992% Item 12: IN SCHEDULE 13G - TO BE INCLUDED IN

STATEMENTS FILED PURSUANT TO RULE 13d-1(c)

Item 1(a). Name of Issuer:

Insmed Incorporated

Item 1(b). Name of Issuer's Principal Executive Offices:

8720 Stony Point Parkway Suite 200 Richmond, VA 23235 USA

Item 2(a). Name of Person Filing: FMR LLC

Item 2(b). Address or Principal Business Office or, if None, Residence:

82 Devonshire Street, Boston, Massachusetts 02109 Item 2(c). Citizenship: Not applicable Title of Class of Securities: Item 2(d). Common Stock Item 2(e). CUSIP Number: 457669307 Item 3. This statement is filed pursuant to Rule 13d-1(c) Item 4. Ownership (a) Amount Beneficially Owned: 4,700,346 Percent of Class: 14.992% (b) Number of shares as to which such (C) person has: sole power to vote or to direct (i) the vote: 1,893,146 (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 4,700,346 shared power to dispose or to (iv) direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Common Stock of Insmed Incorporated. The interest of one person, Beacon Bioventures Limited Partnership, an investment company registered under the Investment Company Act of 1940, in the Common Stock of Insmed Incorporated, amounted to 1,869,084 shares or 5.962% of the total outstanding Common Stock at February 28, 2013.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

See attached Exhibit A.

Item 8. Identification and Classification of Members of the Group.

Not applicable. See attached Exhibit A.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purpose or effect.

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

March 08, 2013 Date

/s/ Scott C. Goebel Signature

Scott C. Goebel Duly authorized under Power of Attorney effective as of June 1, 2008 by and on behalf of FMR LLC and its direct and indirect subsidiaries

SCHEDULE 13G - TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(c)

Pursuant to the instructions in Item 7 of Schedule 13G, Fidelity Management & Research Company ("Fidelity"), 82 Devonshire Street, Boston, Massachusetts 02109, a whollyowned subsidiary of FMR LLC and an investment adviser registered under Section 203 of the Investment Advisers Act of 1940, is the beneficial owner of 2,807,200 shares or 8.954% of the Common Stock outstanding of Insmed Incorporated ("the Company") as a result of acting as investment adviser to various investment companies registered under Section 8 of the Investment Company Act of 1940.

Edward C. Johnson 3d and FMR LLC, through its control of Fidelity, and the funds each has sole power to dispose of the 2,807,200 shares owned by the Funds.

Neither FMR LLC nor Edward C. Johnson 3d, Chairman of FMR LLC, has the sole power to vote or direct the voting of the shares owned directly by the Fidelity Funds, which power resides with the Funds' Boards of Trustees.

Fidelity carries out the voting of the shares under written guidelines established by the Funds' Boards of Trustees.

The ownership of one investment company, Beacon Bioventures Limited Partnership, amounted to 1,869,084 shares or 5.962% of the Common Stock outstanding. Beacon Bioventures Limited Partnership has its principal business office at 82 Devonshire Street, Boston, Massachusetts 02109.

Beacon Bioventures Limited Partnership and Beacon Bioventures Principals Limited Partnership, 82 Devonshire Street, Boston, MA 02109, each a Delaware limited partnership, are the beneficial owners of 1,869,084 shares and 12,668 shares, respectively, or 5.962% and 0.040% respectively, of the Common Stock outstanding. Beacon Bioventures Advisors Limited Partnership is the general partner of Beacon Bioventures Limited Partnership and Beacon Bioventures Principals Limited Partnership. The general partner of Beacon Bioventures Advisors Limited Partnership is Fidelity Biosciences Corp., a wholly-owned subsidiary of FMR LLC.

Members of the family of Edward C. Johnson 3d, Chairman of FMR LLC, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC.

Pyramis Global Advisors Trust Company ("PGATC"), 900 Salem Street, Smithfield, Rhode Island, 02917, an indirect wholly-owned subsidiary of FMR LLC and a bank as defined in Section 3(a)(6) of the Securities Exchange Act of 1934, is the beneficial owner of 11,394 shares or 0.036% of the outstanding Common Stock of the Insmed Incorporated as a result of its serving as investment manager of institutional accounts owning such shares.

Edward C. Johnson 3d and FMR LLC, through its control of Pyramis Global Advisors Trust Company, each has sole dispositive power over 11,394 shares and sole power to vote or to direct the voting of 11,394 shares of Common Stock owned by the institutional accounts managed by PGATC as reported above.

SCHEDULE 13G - TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(c) RULE 13d-1(f)(1) AGREEMENT

The undersigned persons, on March 08, 2013, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the

Common Stock of Insmed Incorporated at February 28, 2013.

FMR LLC

By /s/ Scott C. Goebel Scott C. Goebel Duly authorized under Power of Attorney effective as of June 1, 2008, by and on behalf of FMR LLC and its direct and indirect subsidiaries Edward C. Johnson 3d By /s/ Scott C. Goebel Scott C. Goebel Duly authorized under Power of Attorney effective as of June 1, 2008, by and on behalf of Edward C. Johnson 3d Fidelity Management & Research Company

> By /s/ Scott C. Goebel Scott C. Goebel Senior V.P. and General Counsel